Genotoxicity Testing of Silver-Containing Collagen Wound Dressings: Standards, Strategy, and Evaluat

Genotoxicity testing of silver-containing collagen wound dressings is a critical component of the biological safety evaluation required under ISO 10993-3 for medical devices that contact compromised skin and wounds for prolonged periods. Because silver ions and silver nanoparticles are intentionally released for antimicrobial effect and have documented potential to interact with DNA, regulators expect a well-designed genotoxicity test battery supported by extractable/leachable data and a formal risk assessment. This article explains the rationale, sample preparation, standard test battery, methods, acceptance criteria, and regulatory applications for genotoxicity evaluation of these advanced wound care products.

Technical Overview

Silver-containing collagen wound dressings combine a collagen-based matrix, which supports moist wound healing and cellular migration, with ionic or nanoparticulate silver, which provides broad-spectrum antimicrobial activity against wound pathogens. These dressings are typically classified as surface medical devices that contact breached or compromised skin for durations exceeding 24 hours and up to 30 days, placing them in a category where ISO 10993-1 requires a comprehensive biological evaluation, including genotoxicity.

The genotoxicity concern for this product class arises from several sources. Free silver ions can penetrate cells, generate reactive oxygen species (ROS), and bind directly to DNA and proteins, while silver nanoparticles have been reported to induce DNA strand breaks and chromosomal damage in in vitro systems. In addition, the collagen source material, crosslinking agents, residual processing chemicals, and sterilization by-products (for example, ethylene oxide residues or radiation-induced degradation products) may contribute to the overall genotoxic hazard profile of the finished device.

ISO 10993-3:2014, together with ISO 10993-1:2018 and ISO 10993-12:2021, establishes the framework for evaluating genotoxicity as part of a risk management approach aligned with ISO 14971. In most cases, an in vitro test battery is conducted first; in vivo testing is only triggered when in vitro results are positive and the hazard cannot be excluded by chemical characterization and toxicological risk assessment.

Testing Samples

Finished Dressing Extracts

The preferred test article is the final finished dressing in its sterilized, ready-to-use condition, since only the finished device reflects all manufacturing, crosslinking, silver-loading, and sterilization influences. Extracts are prepared in both a polar vehicle (such as physiological saline or serum-free culture medium) and a non-polar vehicle (such as sesame seed oil or DMSO-compatible systems) to capture leachables of differing polarity.

Extraction Parameters

Extraction follows ISO 10993-12 using a surface-area-to-volume ratio appropriate to the device geometry, commonly 3 cm²/mL for membrane-like dressings or 0.1–0.2 g/mL for porous, foam-like, or hydrogel structures where surface area cannot be reliably determined. Standard extraction conditions include 37°C for 24 hours, 50°C for 72 hours, or 70°C for 24 hours; the mildest condition consistent with producing an adequate extraction is generally selected. Extraction is performed under aseptic conditions with agitation, and extracts are used promptly to avoid silver ion precipitation or adsorption artifacts.

Special Considerations for Silver Release

Because genotoxicity evaluation is intended to detect DNA damage rather than cytotoxicity, dose-range finding is essential. Silver released from the dressing may exert strong bactericidal and cytotoxic effects that confound assay readouts; therefore, the silver concentration in extracts is often quantified analytically (for example, by ICP-MS or ICP-OES) so that tested doses remain below overtly cytotoxic levels while still providing the maximum achievable concentration required by the standards.

Testing Items

A standard in vitro genotoxicity battery for silver-containing collagen dressings, per ISO 10993-3, typically includes the following test items:

• Bacterial reverse mutation test (Ames test) — detects point mutations (base-pair substitutions and frameshifts) in Salmonella typhimurium strains (such as TA98, TA100, TA1535, TA1537) and Escherichia coli WP2 uvrA (pKM101), with and without metabolic activation (S9 mix).
• In vitro mammalian chromosomal aberration test — detects structural and numerical chromosome damage in Chinese hamster ovary (CHO), Chinese hamster lung (CHL), or human lymphocyte cultures.
• In vitro mammalian cell micronucleus test — detects clastogenic and aneugenic effects using human peripheral blood lymphocytes or TK6/CHO cells, evaluated by microscopy or flow cytometry.
• Mouse lymphoma assay (alternatively) — detects gene mutation at the thymidine kinase locus in L5178Y cells, which can substitute within a battery to broaden mutation endpoint coverage.
• In vivo micronucleus test (conditional) — conducted in rodent bone marrow or peripheral blood erythrocytes only when justified by positive in vitro findings and insufficient chemical characterization data.

Testing Methods

General Test Design Principles

All assays are performed in compliance with OECD Principles of Good Laboratory Practice and the relevant OECD Test Guidelines (TG 471 for the Ames test, TG 473 for chromosomal aberration, TG 487 for in vitro micronucleus, and TG 474 for the in vivo micronucleus test), integrated with the medical-device-specific provisions of ISO 10993-3 and the GB/T 16886 series for submissions in China. Each assay includes concurrent negative (vehicle) controls, strain- and cell-appropriate positive controls (such as sodium azide, 2-nitrofluorene, methyl methanesulfonate, mitomycin C, cyclophosphamide, and benzo[a]pyrene with S9), and demonstrable assay validity.

Bacterial Reverse Mutation Test

Extracts are tested in at least five tester strains in the plate-incorporation or pre-incubation method, both with and without an exogenous metabolic activation system. Because silver is bactericidal, preliminary testing verifies that the extract does not suppress background bacterial growth, which would mask revertant colony detection; where bactericidal activity is demonstrated, dilution series or membrane-separated exposure designs are applied, and this deviation is justified in the report. A result is considered positive when a reproducible, dose-related increase in revertant counts of at least twofold exceeds the solvent control.

In Vitro Chromosomal Aberration and Micronucleus Tests

Mammalian cells are exposed to the extract at multiple concentrations determined by a cytotoxicity range-finding study, targeting the highest dose at approximately 55±5% cytotoxicity (relative population doubling or replication index) with lower doses at appropriate spacing. Short-term exposures (3–6 hours) are performed with and without S9 activation, followed by recovery, and a continuous exposure (approximately 1.5 cell cycles) is performed without S9. For the micronucleus assay, cytokinesis-block or flow-cytometric scoring of at least 2,000 cells per concentration is applied, with cytostasis quantified and the cytokinesis-block proliferation index reported. A positive response requires a statistically significant, concentration-related increase exceeding the historical control limits of the laboratory.

In Vivo Follow-Up Strategy

If any in vitro assay is positive, ISO 10993-3 requires an in vivo test to assess relevance under whole-animal conditions, most commonly the rodent micronucleus test with bone marrow or peripheral blood sampling at 24 and 48 hours after dosing, including a toxicokinetic or disposition justification demonstrating that the target tissue was actually exposed to leachable silver or other candidate mutagens. Alternatively, an in vivo comet assay may be justified for site-of-contact or tissue-specific DNA damage assessment.

Evaluation and Interpretation

Results are never interpreted in isolation. The final genotoxicity conclusion integrates assay outcomes with extractable and leachable chemical characterization (ISO 10993-18), silver speciation and release-kinetics data, toxicological risk assessment, and the device's clinical use conditions. Weight-of-evidence evaluation frequently demonstrates that in vitro effects of silver occur only at cytotoxic concentrations, supporting a conclusion of no relevant genotoxic risk under clinical exposure.

Applications

Genotoxicity test data for silver-containing collagen wound dressings support multiple regulatory and quality objectives:

• Biological safety evaluation reports required for marketing authorization submissions in China under NMPA medical device registration, in the United States under FDA 510(k) or PMA review, and in the European Union under the MDR (Regulation (EU) 2017/745) with notified body conformity assessment.
• Compilation of the ISO 10993-1 biological evaluation plan and final report forming part of the technical documentation or device master file.
• Inputs to the ISO 14971 risk management file, including hazard identification and benefit-risk justification for intentional silver release.
• Verification of biological equivalence after material, supplier, crosslinking, silver-loading, or sterilization changes.
• Due-diligence testing by manufacturers and developers of advanced wound care products at accredited third-party laboratories.

FAQ

Why is genotoxicity testing mandatory for silver-containing collagen wound dressings?

These dressings contact breached skin for prolonged durations, a category for which ISO 10993-1 identifies genotoxicity as a required endpoint. The intentional release of silver, a substance with documented DNA-reactive potential under certain conditions, reinforces the regulatory expectation for a formal genotoxicity evaluation.

Which standards govern the testing?

The primary standards are ISO 10993-3 (genotoxicity, carcinogenicity, and reproductive toxicity tests), ISO 10993-1 (evaluation framework), ISO 10993-12 (sample preparation), and ISO 10993-33 (guidance on genotoxicity test methods), supplemented by OECD Test Guidelines 471, 473, 474, 487, and 476. For Chinese registration, the corresponding GB/T 16886 series applies with essentially aligned technical content.

How is the antimicrobial effect of silver handled in the Ames test?

Because silver's bactericidal action can suppress revertant growth and mask mutagenicity, laboratories verify that test concentrations do not inhibit bacterial background growth, use dilution series when necessary, and document these adaptations so that the assay remains scientifically valid.

What happens if a positive in vitro result is obtained?

A positive in vitro finding triggers a follow-up strategy: first, chemical characterization of the extract to identify the responsible leachable, then either an in vivo assay (such as the rodent micronucleus test) or a weight-of-evidence argument demonstrating that the effect occurs only under non-physiologic, cytotoxic conditions irrelevant to clinical exposure.

How many samples are needed and what is the typical timeline?

Typically, a sufficient number of finished, sterilized dressings to yield the required extract volume for both polar and non-polar vehicles across all assays is needed, often corresponding to the equivalent of 300–600 cm² of material. The full in vitro battery, including range-finding studies, generally requires 8 to 12 weeks, with additional time for any in vivo follow-up or repeat testing triggered by protocol-defined criteria.